ASH 2022 | A Phase II trial evaluating E7820 in patients with AML with splicing factor mutations
In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a Phase II study evaluating the safety and efficacy of E7820 in patients with acute myeloid leukemia (AML) with splicing factor mutations (NCT05024994). Although the clinical efficacy of this agent was limited, Dr Stein highlights the promising biological activity observed and the possibility of exploring combination approaches to augment the activity of E7820. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PTC Therapeutics and Syros: Membership on an entity’s Board of Directors or advisory committees; Syndax: Consultancy, Research Funding; Amgen, AbbVie, Seattle Genetics, and Biotheryx: Consultancy; Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Auron Therapeutics: Current equity holder in private company; PinotBio, Bristol Myers Squibb, Jazz Pharmaceuticals, Foghorn Therapeutics, Blueprint Medicines, Gilead Sciences, Janssen Pharmaceuticals: Consultancy; Bayer: Research Funding.
